Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia
March 2001
Pfizer will soon market Geodon (ziprasidone), a new atypical antipsychotic for schizophrenia.
Geodon will be widely used because it appears to cause less weight gain than other atypicals...Zyprexa, Seroquel, or Risperdal.
This is important. Weight gain is a common reason why patients discontinue therapy...and it increases the risk of developing diabetes and heart disease.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote